COGT (Cogent Biosciences) Other Financing: $509.32 Mil (TTM As of Mar. 2026)


COGT Cogent Biosciences Inc COGT
25 GF Score
Price $38.05
! 5 Warning Signs
View Full Analysis

What is Cogent Biosciences Other Financing?

Cogent Biosciences COGT +0.26% 25 Other Financing is $509.32 Mil as of Mar. 2026. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 5 warning signs investors should review.

Cogent Biosciences's Other Financing for the three months ended in Mar. 2026 was $6.82 Mil.

Cogent Biosciences's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $509.32 Mil.

Cogent Biosciences Other Financing Historical Data

* Premium members only.

The historical data trend for Cogent Biosciences's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogent Biosciences Other Financing Chart

Cogent Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 1.61 1.72 1.12 501.15

Cogent Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.00 1.58 500.92 6.82
COGT
25GF Score
Cogent Biosciences Inc COGT
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogent Biosciences Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $509.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $509.32 Mil mean?
Cogent Biosciences (COGT) has a Other Financing of $509.32 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cogent Biosciences and its competitors.
Is Cogent Biosciences' Other Financing too high?
Cogent Biosciences' current Other Financing is $509.32 Mil. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Other Financing compare to SRRK and RYTM?
Cogent Biosciences' Other Financing of $509.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cogent Biosciences and its competitors. Cogent Biosciences's current Other Financing is $509.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Other Financing of $509.32 Mil. The current Other Financing is $509.32 Mil. Cogent Biosciences' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Other Financing is $509.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cogent Biosciences Business Description

Address 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score

Get the complete analysis for COGT

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.05
Price